Concerned about the increasing uncertainty that exists about the patent-eligibility of biotech products that incorporate naturally occurring substances and methods of using those products in therapeutic, diagnostic or industrial processes, the Biotechnology Innovation Organization (BIO) submitted an amicus brief in Natural Alternatives Inc. v. Creative Compounds LLC, which is on appeal to the U.S. Court of Appeal for the Federal Circuit.